Featured Article Cover Story Research & Innovation Financing & Partnerships Product Launches Mergers & Acquisitions Regulatory Updates At a Glance Merck Animal Health Expands Poultry Tech Portfolio Acquisition Merck Animal Health has agreed to acquire TARGAN, adding advanced po...
Quick Takeaways: Why It Matters? Unlike drugs that carry safety concerns or diminishing effectiveness, LIFU aims to provide a non-invasive alternative to nerve blocks and radiofrequency ablation without systemic exposure, which could reduce reliance on medications and invasive procedures. ...
Quick Takeaways: Why It Matters? At scale (100,000+ ER visits already), AI-assisted documentation can meaningfully cut admin time, speed chart closure, and let vets and scribes reallocate hours to procedures, decision‑making, and client communication, helping VEG differentiate ...
Quick Takeaways: Why It Matters? This partnership is designed to scale Rebound High Performance PRP across the US veterinary market by combining epiq’s distribution reach with Vetirus’s product and regulatory credentials, removing a key barrier to adoption-access to e...
Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
The European Medicines Agency (EMA) is continuing to accelerate innovation in animal healthcare, with its 2025 veterinary approvals reflecting strong momentum across poultry vaccines, companion animal therapeutics, livestock disease prevention, and aquaculture solutions. The latest wave of...
Quick Takeaways Why It Matters? Medline’s move is a smart adjacency play: it brings a proven sterile-kitting model from human healthcare into animal health, where shelters and high-volume clinics care a lot about speed, consistency, and labor savings. The big ma...
Quick Takeaways Why It Matters? Gelteq’s animal health trial gives it a foothold in the large antiparasitic market and turns its gel-based platform into a potential formulation partner for veterinary pharma, not just nutraceuticals. If the data support a later FDA filing,...
Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
